Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday while also sharing more details on the internal culling of its R&D pipeline ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to declining drug franchises.

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... Collaboration revenues represent 50% of the net revenues recorded when Biogen ships ZURZUVAE to the distributors. For the year ended December ...

Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called ...